• IL-10 has key anti-inflammatory and immunomodulatory properties. Defective IL-10 signaling is associated with early-onset inflammatory bowel disease.
• Colitis-associated colorectal cancer (CA-CRC) occurs in areas of chronic inflammation, and the risk is proportionate to the duration and severity of inflammation. Inflammatory bowel disease (IBD) is associated with a significant risk for colorectal carcinoma (CRC); up to 30% of patients with IBD develop CRC in their lifetime.
  • Patients with ulcerative colitis, particularly pancolitis, are at highest risk.

Crohn’s Disease (CD)

Ulcerative Colitis (UC)

• ASCA is positive in about 55% of those with Crohn disease, but are uncommon in ulcerative colitis; conversely, p-ANCA is positive in about 70% of patients with ulcerative colitis, but in less than 20% of patients with Crohn disease.

• infliximab induces & maintains remission in IBD